• Dapps:16.23K
  • Blockchains:78
  • Active users:66.47M
  • 30d volume:$303.26B
  • 30d transactions:$879.24M

BIO Protocol and NuDAO Join Forces to Accelerate Decentralized Science Development

user avatar

by Giorgi Kostiuk

a year ago


BIO Protocol and NuDAO have entered into a partnership aimed at strengthening the decentralized science ecosystem through strategic resource allocation and collaboration.

A Transformative Partnership

A recent press release announced NuDAO's strategic allocation of 6.9% of its treasury to BIO Protocol, highlighting a long-term collaboration to accelerate the decentralized science ecosystem. This partnership combines NuDAO's technological expertise in biotech and AI with BIO Protocol's established DeSci infrastructure.

This strategic partnership demonstrates our confidence in BIO Protocol’s vision and our shared commitment to advancing decentralized science.NuDAO

Key Elements of the Partnership

The partnership includes scientific and technical collaborations: * Joint Development: NuDAO and BIO Protocol will collaborate on significant scientific research initiatives, focusing on IP and NFT development. * Co-Incubation Projects: Both organizations will incubate promising research projects together, providing shared resources and expertise. * Governance: Both entities will actively participate in each other's governance frameworks, promoting collaboration and shared decision-making in DeSci development.

The Role of the CRISPR Token

A key component of the partnership is the integration of NuDAO's CRISPR token, which powers the research ecosystem. CRISPR will gain access to BIO Protocol’s research resources, driving innovation. CRISPR token holders will have the opportunity to participate in key decisions, influencing the future of decentralized science. The collaboration will enhance CRISPR’s position within the broader DeSci network, unlocking opportunities for growth and innovation.

The partnership aims to create a global decentralized research community enabling borderless collaboration. It supports the commercialization of biotech innovations, such as rare disease research and longevity research.

0

Rewards

chest
chest
chest
chest

More rewards

Discover enhanced rewards on our social media.

chest

Other news

MYX Finance Emerges as a Transformative Protocol in Decentralized Futures Market

chest

MYX Finance is gaining significant investor interest as a decentralized perpetual futures protocol with innovative features.

user avatarRajesh Kumar

Regulatory Developments Impacting MYX Finance's Growth Trajectory

chest

Evolving regulatory guidelines are shaping the compliance architecture of MYX Finance, ensuring adherence to investor protection mechanisms and improving institutional adoption rates.

user avatarMiguel Rodriguez

MYX Finance's Unique Features Drive Adoption in Decentralized Derivatives

chest

MYX Finance's cross-chain compatibility and competitive fee structure are driving adoption in the decentralized derivatives market, particularly in Asian markets.

user avatarGustavo Mendoza

Layered Risks of Restaking: A Cautionary Tale

chest

The complexity of restaking introduces multiple risks, including slashing and centralization pressures.

user avatarArif Mukhtar

The Mirage of Yield: Understanding Restaking

chest

Restaking offers high yields that are often artificial and may not reflect genuine economic value.

user avatarLuis Flores

Restaking Risks in DeFi: A Growing Concern

chest

The rise of restaking protocols in DeFi has led to increased risks for validators and the overall security of networks.

user avatarMaria Gutierrez

Important disclaimer: The information presented on the Dapp.Expert portal is intended solely for informational purposes and does not constitute an investment recommendation or a guide to action in the field of cryptocurrencies. The Dapp.Expert team is not responsible for any potential losses or missed profits associated with the use of materials published on the site. Before making investment decisions in cryptocurrencies, we recommend consulting a qualified financial advisor.